Trandolapril
- TRADE NAMES: Gopten; Mavik (AbbVie); Odrik; Tarka (AbbVie); Udrik
- INDICATIONS: Hypertension
- CLASS: Angiotensin-converting enzyme (ACE) inhibitor, Antihypertensive, Vasodilator
- HALF-LIFE: 6 hours
Alcohol, Aldesleukin, Aliskiren, Allopurinol, Alpha blockers, Amiloride, Angiotensin II receptor antagonists, Antacids, Antidiabetics, Antipsychotics, Anxiolytics and hypnotics, Baclofen, Beta blockers, Calcium channel blockers, Clonidine, Corticosteroids, Cyclosporine, Diazoxide, Diuretics, Estrogens, General anesthetics, Gold & Gold Compounds, Heparins, Hydralazine, Insulin, Levodopa, Lithium, MAO inhibitors, Metformin, Methyldopa, Minoxidil, Moxisylyte, Moxonidine, Nitrates, Nitroprusside, NSAIDs, Potassium salts, Spironolactone, Sulfonylureas, Tizanidine, Triamterene, Trimethoprim
PREGNANCY CATEGORY: D
category C in first trimester; category D in second and third trimesters
Contra-indicated in patients with hereditary/idiopathic angioedema and in patients with a history of angioedema related to previous treatment with an ACE inhibitor.
Tarka is trandolapril and verapamil.
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
Page last updated 08/01/2022
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
